NRX Pharmaceuticals, Inc.
3.0500+0.05 (+1.67%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · NRXP · USD
Key Stats
Market Cap
72.50MP/E (TTM)
-Basic EPS (TTM)
-2.21Dividend Yield
0%Recent Filings
8-K
HOPE acquires Cohen clinic
NRx Pharmaceuticals' subsidiary HOPE Therapeutics completed its acquisition of a strategic minority interest in Cohen & Associates on October 17, 2025, integrating the Sarasota-based interventional psychiatry clinic into the HOPE Network. Dr. Rebecca Cohen, a TMS expert with over a decade of leadership, was appointed Medical Director to oversee Florida operations, with immediate expansion planned in Western Florida and Palm Beach. The move bolsters HOPE's offerings in ketamine and TMS for suicidal depression and PTSD. Acquisition expected to boost revenue and EBITDA.
8-K
FDA grants ketamine petition
NRx Pharmaceuticals scored FDA approval for its Suitability Petition on September 24, 2025, greenlighting the proposed strength of KETAFREE™, a single-patient, preservative-free ketamine that ditches toxic Benzethonium Chloride from multi-dose vials. This clears the path for immediate re-filing of the Abbreviated New Drug Application, targeting the $750 million ketamine market while aligning with U.S. policy pushes to reshore sterile drugs and purge harmful preservatives. FDA moves fast. The company eyes quick market entry, separate from its NRX-100 push for suicidal depression, though regulatory hurdles persist.
8-K
NRx completes Dura Medical acquisition
NRx Pharmaceuticals completed its acquisition of Dura Medical on September 8, 2025, integrating the Florida-based interventional psychiatry clinics in Naples and Ft. Myers into subsidiary HOPE Therapeutics. The deal, structured with cash, convertible membership interests, and performance-based earn-outs, adds revenue-generating, EBITDA-positive operations offering ketamine therapy and TMS for depression and PTSD, targeting veterans via VA partnerships. Stephen Durand steps in as Florida clinic operations director. This bolsters HOPE's network expansion amid rising suicide rates, though regulatory and integration risks persist.
8-K
NRx raises $8.8M for HOPE launch
NRx Pharmaceuticals raised $8.8 million in gross proceeds from experienced biotech investors via a registered direct offering and at-the-market program, featuring no warrants or variable rates. This capital fuels the September 2025 rollout of HOPE Therapeutics clinics, blending ketamine, transcranial magnetic stimulation, and hyperbaric oxygen for suicidal depression and PTSD. Matthew Rockefeller joins the advisory board. Funds bolster neuroplastic treatment access.
10-Q
Q2 FY2025 results
NRx Pharmaceuticals narrowed its Q2 operating loss to $3.7M from $7.1M a year earlier, thanks to R&D expenses dropping to $1.0M from $2.8M as clinical milestones advanced. Yet net loss widened to $17.6M from $7.9M, driven by $5.6M in fair value changes on convertible notes and $6.4M on warrant liabilities—gaps exceeding 20% from operating figures due to these non-cash items. Cash climbed to $2.9M from $1.4M at year-start, fueled by $9.0M in financing like ATM offerings, though free cash flow isn't disclosed in the 10-Q. HOPE Therapeutics inked deals for clinic acquisitions, pending closes. Regulatory wins include Fast Track for NRX-100. Funding remains tight amid biotech volatility.
AMLX
Amylyx Pharmaceuticals, Inc.
13.89-0.43
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CNSP
CNS Pharmaceuticals, Inc.
7.60-0.71
LBRX
LB Pharmaceuticals Inc
15.65-0.92
NERV
Minerva Neurosciences, Inc
4.23-0.37
NLSP
NLS Pharmaceutics Ltd.
0.74-0.31
NMRA
Neumora Therapeutics, Inc.
2.50-0.09
NRSN
NeuroSense Therapeutics Ltd.
1.06-0.06
NVCT
Nuvectis Pharma, Inc.
6.77+0.34
XENE
Xenon Pharmaceuticals Inc.
42.30-0.23